Bernstein reiterates Summit Therapeutics stock rating on trial concerns
Covered in this story
Analyst targets on Summit Therapeutics
- Citizens JMP: $16.9 → $40 by Sep 2027 · Market Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $SMMT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Summit Therapeutics →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.